MX366038B - 1, 2-dioles y 1,2,3-trioles antiespasmodicos. - Google Patents

1, 2-dioles y 1,2,3-trioles antiespasmodicos.

Info

Publication number
MX366038B
MX366038B MX2014014634A MX2014014634A MX366038B MX 366038 B MX366038 B MX 366038B MX 2014014634 A MX2014014634 A MX 2014014634A MX 2014014634 A MX2014014634 A MX 2014014634A MX 366038 B MX366038 B MX 366038B
Authority
MX
Mexico
Prior art keywords
triols
diols
antispasmodic
agents
inflammatory
Prior art date
Application number
MX2014014634A
Other languages
English (en)
Other versions
MX2014014634A (es
Inventor
Sanghvi Shah Priti
V Shah Mandar
Original Assignee
Prima Innovations Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prima Innovations Llc filed Critical Prima Innovations Llc
Publication of MX2014014634A publication Critical patent/MX2014014634A/es
Publication of MX366038B publication Critical patent/MX366038B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden 1,2-dioles alifáticos C4-C8 y 1, 2, 3-trioles alifáticos C4-C8 y su uso para aliviar los espasmos asociados con el dolor. Estos agentes pueden ser administrados tópica u oralmente y pueden combinarse con agentes antiinflamatorios tales como un fármaco antiinflamatorio no esteroideo o corticoesteroide. La administración de los 1 ,2-dioles alifáticos C4-C8 y 1,2,3-trioles alifáticos C4-C8 con vitamina D3 es indicada para condiciones tales como pérdida ósea, aumento de peso y enfermedades autoinmunes tales como lupus y artritis reumatoide.
MX2014014634A 2012-05-31 2013-05-24 1, 2-dioles y 1,2,3-trioles antiespasmodicos. MX366038B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261653737P 2012-05-31 2012-05-31
US13/798,822 US8853189B2 (en) 2012-05-31 2013-03-13 Antispasmodic 1,2-Diols and 1,2,3-triols
PCT/US2013/042583 WO2013181084A1 (en) 2012-05-31 2013-05-24 Antispasmodic 1,2-diols and 1,2,3-triols

Publications (2)

Publication Number Publication Date
MX2014014634A MX2014014634A (es) 2015-08-06
MX366038B true MX366038B (es) 2019-06-25

Family

ID=49670995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014634A MX366038B (es) 2012-05-31 2013-05-24 1, 2-dioles y 1,2,3-trioles antiespasmodicos.

Country Status (8)

Country Link
US (2) US8853189B2 (es)
EP (1) EP2854782B1 (es)
JP (1) JP5890939B2 (es)
BR (1) BR112014029691B1 (es)
CA (1) CA2874961C (es)
MX (1) MX366038B (es)
RU (1) RU2657556C2 (es)
WO (1) WO2013181084A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7025129B2 (ja) * 2017-05-17 2022-02-24 小林製薬株式会社 筋痙攣治療剤

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1276097A (en) 1968-09-09 1972-06-01 Orsymonde Improvements in or relating to phloroglucinol derivatives
FR2068442A1 (en) 1969-11-24 1971-08-27 Buzas Andre Diproqualone camphosulphonate noramidopyrine mixtures - having analgesic properties
US4076937A (en) 1973-12-17 1978-02-28 Warner-Lambert Company Dibenzyl glycolic acid derivatives
US4119730A (en) 1976-05-18 1978-10-10 Chimicasa Gmbh Treating muscle spasms
CA1165240A (en) 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4677101A (en) 1983-09-26 1987-06-30 Merck & Co., Inc. Substituted dihydroazepines useful as calcium channel blockers
CA2112751A1 (en) * 1991-07-03 1993-01-21 Charles J. Ii Betlach Composition and method for transdermal delivery of diclofenac
EG20380A (en) 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
JP3526887B2 (ja) 1993-04-23 2004-05-17 帝國製薬株式会社 消炎鎮痛外用貼付剤
CA2259316A1 (en) 1996-07-01 1998-01-08 Bridge Pharma, Inc. Smooth muscle spasmolytic agents, compositions and methods of use thereof
EP0868915A1 (en) 1997-04-02 1998-10-07 Panacea Biotec Limited An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium
WO2002051395A1 (en) 1998-05-28 2002-07-04 Codon Pharmaceuticals, Inc. Treatment of neurodegenerative diseases
HUP9802716A3 (en) 1998-11-25 2000-08-28 Chinoin Gyogyszer Es Vegyeszet Pharmaceutical composition of analgesic activity
DK1194109T3 (da) 1999-06-25 2004-10-25 Durham Pharmaceuticals Ltd Topiske formuleringer omfattende hud-gennemtrængningsmidler samt anvendelse deraf
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20040151771A1 (en) 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
ATE545627T1 (de) 2003-05-23 2012-03-15 Bridge Pharma Inc Glattmuskelspasmolytika
US20060018867A1 (en) 2004-05-12 2006-01-26 Ichimaru Pharcos Co., Ltd Cosmetic composition and production thereof
WO2006044290A2 (en) 2004-10-12 2006-04-27 Board Of Trustees Of Michigan State University Biosynthesis of philoroglucinol and preparation of 1,3-dihydroxybenzene therefrom
KR20070093079A (ko) 2004-11-29 2007-09-17 암브리아 더마톨로지 아베 적어도 세 개의 다른 디올을 포함하는 조성물
EP1898880A2 (en) 2005-06-16 2008-03-19 Warner Chilcott Company Inc. Gel compositions for topical administration
US8318973B2 (en) 2005-10-21 2012-11-27 Bezwada Biomedical, Llc Functionalized sinapic acid and methyl sinapate
WO2007098135A2 (en) 2006-02-21 2007-08-30 Inolex Investment Corporation Anti-microbial compositions
BRPI0717769A2 (pt) 2006-10-17 2013-11-05 Nuvo Res Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio
EP2514407A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
PL3075401T3 (pl) 2007-11-29 2024-08-19 Inolex Investment Corporation Środek konserwujący dla kompozycji kosmetycznych, toaletowych i farmaceutycznych
US20090182054A1 (en) * 2008-01-10 2009-07-16 Jerry Zhang Topical compositions containing solubilized dicarboxylic acids
ES2391913T3 (es) 2008-06-13 2012-12-03 Clariant Finance (Bvi) Limited Composiciones cosméticas o farmacéuticas que comprenden polisiloxanos modificados con al menos un grupo carbamato
AU2009310437A1 (en) 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
SG10201401297QA (en) 2009-04-08 2014-08-28 Cadila Healthcare Ltd Stable pharmaceutical compositions of diclofenac
US20120213717A1 (en) 2011-02-18 2012-08-23 Mcneil-Ppc, Inc. Soothing Agents
KR102058256B1 (ko) 2011-06-17 2020-01-22 버그 엘엘씨 흡입성 약제학적 조성물들

Also Published As

Publication number Publication date
EP2854782B1 (en) 2018-01-31
RU2657556C2 (ru) 2018-06-14
JP2015518046A (ja) 2015-06-25
EP2854782A1 (en) 2015-04-08
US20130324504A1 (en) 2013-12-05
US20140364401A1 (en) 2014-12-11
CA2874961A1 (en) 2013-12-05
WO2013181084A1 (en) 2013-12-05
RU2014154402A (ru) 2016-07-20
JP5890939B2 (ja) 2016-03-22
MX2014014634A (es) 2015-08-06
BR112014029691A2 (es) 2017-08-22
BR112014029691B1 (pt) 2022-07-12
CA2874961C (en) 2021-02-09
US8853189B2 (en) 2014-10-07

Similar Documents

Publication Publication Date Title
MX2015017215A (es) Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
IN2014DN09434A (es)
IN2014DN09352A (es)
IN2014DN09348A (es)
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
BRPI0806713A8 (pt) Composições de tiacumicinas estáveis
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
IN2014DN09347A (es)
WO2013022243A3 (ko) 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
WO2012129077A3 (en) Peptides for suppressing inflammation
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
EA201291335A1 (ru) Фармацевтические композиции для местного применения
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
IN2015DN02999A (es)
BR112014015578A2 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX366038B (es) 1, 2-dioles y 1,2,3-trioles antiespasmodicos.
TW201613606A (en) Therapeutic drug for chronic renal failure
MX2018011142A (es) Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona.

Legal Events

Date Code Title Description
FG Grant or registration